On September 13, 2021 Celdara Medical, LLC reported that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) Fast-Track award to fund the company’s advancement of CM-CX1, a chimeric antigen receptor (CAR) T cell therapy for the treatment of ovarian clear cell and renal cell carcinomas (Press release, Celdara Medical, SEP 13, 2021, View Source [SID1234587601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Jake Reder, Co-founder and Chief Executive Officer of Celdara Medical, remarked, "We are grateful to the NCI for their continued support of this program. The world has learned a lot about how to use CAR T therapies, and we’re now seeing successes against solid tumors as well as hematologic malignancies. Precise selection of target and indication was always part of this particular program, and we’re now keen to translate that potential into the clinic for the benefit of patients."

"The clinical successes of CAR T cells against hematological malignancies have led us to the pursuit of CAR T therapies against multiple targets for the treatment of solid tumors," Dr. Joana Murad Mabaera, Executive Director of Research at Celdara Medical and lead Principal Investigator on this study noted. "I have been working closely with our industry and academic partners to identify ideal targets for cellular therapies and we have created something unique with CM-CX1. The funding by the National Cancer Institute (NCI) provides us with an exciting opportunity to translate our promising research and make this therapeutic option accessible to patients."
Research reported in this press release is supported by the National Cancer Institute of the National Institutes of Health under award number R44CA265424. The content is solely the responsibility of Celdara Medical and does not necessarily represent the official views of the National Institutes of Health.